Search the Newsreel

Tandem Diabetes Care Inc (TNDM) Earnings Forecast: Future EPS & Revenue Growth Estimates

TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up

Tandem Diabetes Care (TNDM) reported a Q2 2026 loss of 31 cents per share, which was narrower than expected, though worldwide revenues of $254.6 million missed consensus estimates. Despite the revenue miss, the company's shares rose 19.1% after the announcement, driven by increased pump …

Tandem Diabetes Care, Inc. (TNDM) Investor Outlook: Analyzing 25% Potential Upside with No Sell Ratings

Tandem Diabetes Care, Inc. (TNDM) presents a high-risk, high-reward investment opportunity in the medical devices industry, with analysts projecting a 25% potential upside and no sell ratings. Despite current financial challenges like negative EPS and free cash flow, the company is bullishly positioned above …

Tandem Diabetes Care, Inc. (TNDM) Stock forecasts

Why Tandem Diabetes Care (TNDM) Is Up 14.8% After Reaffirming 2026 Outlook And Highlighting Mobi Momentum

Tandem Diabetes Care (TNDM) saw its stock rise 14.8% after reaffirming its full-year 2026 sales outlook of US$1.07–1.09 billion and highlighting early success with its Pay-As-You-Go pharmacy model and growing adoption of its Mobi platform. The company reported second-quarter sales of US$254.56 million and …

Why Tandem Diabetes Care (TNDM) Is Up 14.8% After Record Q2 Sales And PayGo Momentum

Tandem Diabetes Care (TNDM) saw its stock rise 14.8% after reporting record Q2 2026 worldwide sales of US$254.56 million, a higher gross margin, and a reduced net loss, while reaffirming its full-year sales guidance of US$1.07 billion. The company's new PayGo pharmacy model, which …

Tandem Diabetes Care (TNDM) Could Be 23% Below Fair Value After Q2 Results

Tandem Diabetes Care (TNDM) reported strong Q2 2026 results with record worldwide sales and reaffirmed full-year guidance, leading to a significant rally in its share price. Despite the recent gains, Simply Wall St. suggests that TNDM is still undervalued by 23.4%, with a fair …

Why Did TNDM Stock Jump 5% After Hours Despite Q4 Earnings Miss?

Tandem Diabetes Care (TNDM) Stock Jumps As Margin Recovery Steals The Spotlight

Tandem Diabetes Care's stock surged 19% after its Q2 earnings report, despite a net loss, due to a significant recovery in gross margin to 57%. Revenue grew 6%, and the net loss narrowed by 60%, with strong performance in international pump shipments and an …

Tandem Diabetes Care, Inc. Stock 12‑Month Price Target Raised to $29.5, Implies 57% Upside

Analysts have raised the average 12-month price target for Tandem Diabetes Care, Inc. (TNDM) stock to $29.5, up from $29.19. This new target suggests a potential upside of approximately 57% from its August 6th closing price. The consensus rating among 22 analysts remains a …

Tandem Diabetes Care (NASDAQ:TNDM) Announces Earnings Results, Beats Estimates By $0.01 EPS

Tandem Diabetes Care Announces Second Quarter 2026 Financial Results

Tandem Diabetes Care, Inc. reported strong financial results for Q2 2026, with worldwide sales increasing 6% to $254.6 million and gross margin up 460 basis points to 57%. The company also highlighted strategic achievements, including FDA submissions for Tandem Mobi, expanded global technology solutions, …

Tandem Diabetes Care Inc (TNDM) News, Articles, Events & Latest Updates

Tandem Diabetes Care Inc (TNDM) reported Q2 2026 financial results, including a loss and lagging revenue estimates, despite some key metrics showing positive movement. The company announced upcoming conference presentations, product compatibility expansions, and plans to release Q2 results in August 2026. This news …

Tandem Diabetes Care, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:TNDM)

Tandem Diabetes Care, Inc. published its Q2 2026 earnings call presentation, reporting an EPS of -$0.31, which beat estimates by $0.01. The company's revenue for the quarter was $254.56M, representing a 5.77% year-over-year increase, though it missed revenue expectations by $510.18K. The slide deck …

Tandem Diabetes Care, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:TNDM) 2026-08-07

Tandem Diabetes Care Q2 Earnings Call Highlights

Tandem Diabetes Care (NASDAQ:TNDM) Shares Gap Down - What's Next?

Tandem Diabetes Care (NASDAQ:TNDM) shares gapped down but later rose by 13.8%. Analyst ratings are mixed, with a consensus "Hold" and an average price target of $28.77, though Mizuho lowered its target to $20. The company reported an adjusted loss of $0.31 per share, …

Tandem Diabetes Care seeing early benefits of new pay-as-you-go model

Tandem Diabetes Care (NASDAQ: TNDM) lifts Q2 sales to $254.6M, trims loss

Tandem Diabetes Care reported strong second-quarter 2026 results, with worldwide sales increasing by 6% to $254.6 million and a significant improvement in gross margin to 57%. The company also narrowed its GAAP net loss to $21.2 million and achieved positive Adjusted EBITDA of $6.4 …

Tandem Earnings: Few Surprises as the Firm Makes Progress With Mobi Pump

Is Tandem Diabetes Care Inc (TNDM) a Value Opportunity After Q2 Earnings Miss? GF Score: 66/100

TANDEM DIABETES CARE INC 2026: Revenue $254.56M, EPS ($0.31) — 10-Q Summary

Tandem Diabetes Care Inc. (TNDM) reported its 2026 quarterly results, showing revenue of $254.56 million, an increase from $240.68 million in the previous year. The company significantly reduced its net loss to ($21.17 million) from ($52.4 million) year-over-year, with diluted loss per share narrowing …

Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say

Tandem Diabetes Q2 2026 slides: PayGo model drives margin expansion

Tandem Diabetes Care (NASDAQ:TNDM) reported record Q2 2026 sales of $255 million, despite a slight miss on revenue forecasts, driven by a strategic transition to a "PayGo" pharmacy-based reimbursement model. This new model is expected to more than double lifetime revenue per patient and …

Tandem Diabetes’s (NASDAQ:TNDM) Q2 CY2026 Earnings Results: Revenue In Line With Expectations

Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates

Tandem Diabetes Care, Inc. (TNDM) reported a Q2 loss of $0.31 per share, exceeding the Zacks Consensus Estimate of a $0.34 loss, marking an 8.82% surprise. Despite this, the company's Q2 revenues of $254.56 million missed the consensus estimate by 0.1%, leading to an …

Voya Financial (TNDM holder) discloses 149,088 Tandem Diabetes Care shares in 13G/A

Voya Financial, Inc. has filed an amended Schedule 13G/A, disclosing its beneficial ownership of 149,088 shares of Tandem Diabetes Care, Inc. common stock, which represents a 0.2% stake in the company. Voya Financial asserts sole voting and dispositive power over these shares. The filing …

Tandem’s Control-IQ+ Gets FDA Clearance for Type 1 Diabetes in Pregnancy

Tandem Diabetes Care (TNDM) Rebounds On Growth Hopes, Is The Stock Still Undervalued?

Tandem Diabetes Care (TNDM) has seen a recent rebound in its stock price, with a 31% gain over 30 days, despite longer-term declines. The company is considered 30.8% undervalued with a fair value of $29.20 compared to its current $20.20, driven by expectations of …

Tandem Diabetes earnings on deck as pharmacy shift tests execution

Tandem Diabetes Care Inc. is preparing to announce its second-quarter results, with analysts expecting a loss of 33 cents per share on revenue of $255.1 million. Investors are keenly focused on the company's transition from a traditional durable medical equipment model to a pay-as-you-go …

Tandem Diabetes Earnings: What To Look For From TNDM

Tandem Poised to Launch Tubeless Mobi Pump

Tandem Diabetes, a recent entrant in the insulin pump market, is still working to establish itself as a major competitor, despite launching its original t:slim pump in 2012. The company is poised to launch its new tubeless Mobi pump. Morningstar's analysis suggests it will …

Responsive Playbooks and the TNDM Inflection

This article from Stock Traders Daily discusses an "inflection" point for Tandem Diabetes Care Inc. (NASDAQ: TNDM), indicating strong sentiment and an overweight bias across all time horizons. It provides detailed trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss …